Trial Profile
Phase I Study of Safety and Pharmacokinetics of Pazopanib in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Cetuximab; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors GSK
- 16 Mar 2012 Actual end date changed from Mar 2010 to May 2010 as reported by ClinicalTrials.gov.
- 14 Apr 2010 Actual patient number (24) added as reported by ClinicalTrials.gov.
- 14 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.